Critical Analysis: Pathfinder Cell Therapy (OTCMKTS:PFND) & CollPlant Biotechnologies (NASDAQ:CLGN)

Pathfinder Cell Therapy (OTCMKTS:PFND) and CollPlant Biotechnologies (NASDAQ:CLGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares Pathfinder Cell Therapy and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pathfinder Cell Therapy	N/A	N/A	N/A
CollPlant Biotechnologies	-2,680.00%	-77.05%	-61.43%

Earnings & Valuation

This table compares Pathfinder Cell Therapy and CollPlant Biotechnologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A
CollPlant Biotechnologies	$10.96 million	4.12	-$7.02 million	($1.54)	-2.56

Pathfinder Cell Therapy has higher earnings, but lower revenue than CollPlant Biotechnologies.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pathfinder Cell Therapy and CollPlant Biotechnologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pathfinder Cell Therapy	0	0	0	0	0.00
CollPlant Biotechnologies	0	0	2	1	3.33

CollPlant Biotechnologies has a consensus price target of $12.50, indicating a potential upside of 217.26%. Given CollPlant Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Pathfinder Cell Therapy.

Insider & Institutional Ownership

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 15.1% of Pathfinder Cell Therapy shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

CollPlant Biotechnologies beats Pathfinder Cell Therapy on 6 of the 10 factors compared between the two stocks.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.